Vendor Intelligence Report: Alchemy Peptides

Published 3 Jul 2026. 26-page investigative report on who is behind Alchemy Peptides: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 2 Finnrick lab tests, Alchemy Peptides shows 2 pass / 0 fail — an overall pass rate of 100%. The signal is real but narrow: it covers Retatrutide only, with a current Finnrick rating of 81.14%, and should not validate the broader storefront. Alchemy is comparatively defensible for Retatrutide; BPC-157, stacks, creams, tablets and other untested catalog items remain a different decision. Methodology-divergence charts show threshold sensitivity, not added coverage.

The business record is less clean than the vial data. California and Wyoming registry checks did not resolve a matching Alchemy Peptides entity, the Corona address is a commercial mailbox, and observed payment rails were Zelle, Venmo and Cash App. Prime Alpha Lab is tied to the same operation by branding, address and email, while alchemypeptide.net redirects to the .com without direct ownership proof.

The higher-friction trail sits in COAs and document control. Alchemy's Terms still carry a Peptide Sciences remnant, though the report found no shared ownership, personnel or address overlap. A captured BPC-157 COA runs through Forever Young Pharmacy rather than a visibly accredited analytical-lab portal; later California Board material moved from accusation to withdrawn status, improving current posture without authenticating the COA.

Promotion surface appears concentrated, not sprawling: recurring code-bearing X posts from @adamjohnsonrtd and retained TikTok coupon evidence lacked clear disclosure in the captures. The FDA warning-letter search found no Alchemy entry as of 2026-06-30, but product-by-product lab coverage and channel verification still drive the buyer decision.

Inside the full report:

  • Appendix A Finnrick Laboratory Data with per-product rates and methodology-divergence charts for the single covered product
  • California, Wyoming and OpenCorporates registry checks plus Corona PMB and payment-rail analysis
  • Prime Alpha Lab sister-storefront artifacts and alchemypeptide.net redirect analysis
  • Forever Young Pharmacy COA provenance with California Board of Pharmacy status exhibits
  • Peptide Sciences terms-remnant screenshots, catalog evidence and affiliate-code promotion analysis

Risk assessment

  • BPC-157 and non-Retatrutide COA/verification risk — high: Retatrutide has Finnrick passes, but BPC-157 is documented with a Forever Young Pharmacy COA and no Finnrick coverage exists for BPC-157, TB-500, Tesamorelin/PT-141, stacks, creams or tablets.
  • Corporate traceability and buyer-recourse risk — medium: No CA/WY registration was found for Alchemy Peptides/Alchemy Peptide; the Corona address is a PMB/CMRA and payments are Zelle, Venmo or Cash App.
  • Brand-confusion and document-control risk — medium: Terms still reference Peptide Sciences, Prime Alpha Lab operates as a sister storefront, alchemypeptide.net redirects to the .com, and no public official-channel list was found.
  • Affiliate-promotion and disclosure risk — medium: Recurring code promotion by @adamjohnsonrtd and retained code-bearing influencer evidence lacked clear disclosure and framed products around human outcomes.